Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLASMA phase II study of AZD9291 in plasma T790M-positive advanced non-small cell lung cancer after prior EGFR TKI
KCT0003197Phase 2Completed
- Sponsor
- National University Cancer Institute, Singapore
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by National University Cancer Institute, Singapore. Primary endpoint: Objective response rate. Started Mar 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0003197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003197.